Healthcare utilization disparities among children with high‐risk neuroblastoma treated on Children's Oncology Group clinical trials

Abstract

AbstractIntroductionDisparities in relapse and survival from high‐risk neuroblastoma (HRNBL) persist among children from historically marginalized groups even in highly standardized clinical trial settings. Research in other cancers has identified differential treatment toxicity as one potential underlying mechanism. Whether racial and ethnic disparities in treatment‐associated toxicity exist in HRNBL is poorly understood.MethodsThis is a retrospective study utilizing a previously assembled merged cohort of children with HRNBL on Children's Oncology Group (COG) post‐consolidation immunotherapy trials ANBL0032 and ANBL0931 at Pediatric Health Information System (PHIS) centers from 2005 to 2014. Race and ethnicity were categorized to reflect historically marginalized populations as Hispanic, non‐Hispanic Black (NHB), non‐Hispanic other (NHO), and non‐Hispanic White (NHW). Associations between race‐ethnicity and intensive care unit (ICU)‐level care utilization as a proxy for treatment‐associated toxicity were examined with log binomial regression and summarized as risk ratio (RR) and corresponding 95% confidence interval (CI).ResultsThe analytic cohort included 370 children. Overall, 88 (23.8%) patients required ICU‐level care for a median of 3.0 days (interquartile range [IQR]: 1.0–6.5 days). Hispanic children had nearly three times the risk of ICU‐level care (RR 3.1, 95% CI: 2.1–4.5; fully adjusted RR [aRR] 2.5, 95% CI: 1.6–3.7) compared to NHW children and the highest percentage of children requiring cardiovascular‐driven ICU‐level care.ConclusionChildren of Hispanic ethnicity with HRNBL receiving clinical trial‐delivered therapy were more likely to experience ICU‐level care compared to NHW children. These data suggest that further investigation of treatment‐related toxicity as a modifiable mechanism underlying outcome disparities is warranted.